NCT00203021View on ClinicalTrials.gov

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

PHASE4CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

March 26, 1994

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

Glatiramer acetate

Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.

Trial Locations (11)

14642

Teva Investigational Site 007, Rochester

19104

Teva Investigational Site 001, Philadelphia

21201

Teva Investigational Site 005, Baltimore

48201

Teva Investigational Site 003, Detroit

53719

Teva Investigational Site 011, Madison

77030

Teva Investigational Site 010, Houston

84148

Teva Investigational Site 006, Salt Lake City

87131

Teva Investigational Site 002, Albuquerque

90033

Teva Investigational Site 009, Los Angeles

90095-7077

Teva Investigational Site 004, Los Angeles

06520-8018

Teva Investigational Site 008, New Haven

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY